Patients with lowest BMI have shortest survival in pooled analysis of bev in mCRC

(European Society for Medical Oncology) Patients with the lowest body mass index had the shortest overall survival in an analysis of bevacizumab studies in metastatic colorectal cancer presented for the first time at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news